SHH and medulloblastoma: Due to the poor prognosis of some SHH medulloblastomas, the 2016 WHO consensus conference has reclassified subgroups into: WNT, SHH and TP53 wild-type, SHH and TP53 mutant, and non-WNT/non-SHH (encompassing Group 3 and Group 4 within this subgroup)7.